Your drug bill
has an off switch.
8% of your workforce has an autoimmune condition. Most are on biologics indefinitely — many getting no meaningful relief.
Thymos Health's physician-led program gives members and your plan a path out.
For every 1,000 covered lives,
80 members are on an exponentially rising cost curve.
By the time a patient appears on your biologic spend report, they've been accumulating disease burden for years — fragmented care, failed treatments, and rising healthcare costs that often continue well beyond the drug cost itself.
$300K
"Most patients have never been told that there's another more effective path."
What your members
actually feel.
Thymos drives measurable clinical improvement at every step, guided by 24/7 data monitoring between every consult. This builds trust, optimizes treatment adherence, reduces unnecessary tests and specialist overutilization, and opens the taper window.
$500 to save
$1,000–$25,000 PMPM, indefinitely.
Every month a patient advances through the program, the cost asymmetry compounds. The Thymos fee stays flat. The drug cost disappears.
Patience is the
only input.
Tapering takes months, not weeks. But every engaged patient pays back their full program cost — and then some.
Based on 3-archetype engagement model: early adopter (M6), mid-cycle (M12), slow adopter (M18–M19).
10 participants.
$480K net gain.
Conservative estimate using a $5K/month average biologic AWP. Even slow adopters who taper at month 18 generate net gain within the 24-month window.
Assumes avg biologic AWP $5K/mo · mixed engagement cohort · program fee $500/participant/month. Actual PBM data will sharpen these numbers.
Build your own model — pick a drug, pick a timing →Four steps.
No disruption to HR.
No new clinical workflows. No burden on your benefits team. Thymos does the clinical work — you see the results in a monthly report, first week of every month.
Start with
your real numbers.
The model above uses industry averages. One ask to your health plan or PBM gives you an actual count of eligible members — and a real ROI projection built from your own claims data.
De-identified monthly reporting · Minimum viable cohort: 10 eligible members